Business Context and Reporting Period
Company: Corvus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2019
Reporting Period: Event-based disclosure regarding a press release issued on December 7, 2019.
Business Context: The registrant is an emerging growth company focused on pharmaceutical development. This filing serves as a Regulation FD disclosure to announce the presentation of clinical data.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change disclosed in this filing is the announcement of preclinical and first clinical data from the Phase 1/1b trial of the company's candidate drug, CPI-818. This data was presented at the American Society of Hematology (ASH) Annual Meeting.
Guidance, Outlook, and Risks
- Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the clinical data presentation. The text of the press release is not included in the provided input.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings except as expressly set forth.
- Outlook: No specific financial guidance or future outlook is provided in the text of this 8-K.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to review the specific preclinical and Phase 1/1b clinical data for CPI-818.
- Confirm the implications of the emerging growth company status on financial reporting standards.
- Review the American Society of Hematology (ASH) Annual Meeting proceedings for the detailed presentation referenced.
- Check subsequent filings for any updates on the CPI-818 trial status or financial impact of the clinical progress.